EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway

Lin Zhu, Jiawen Yang, Fengmei Li, Dandan Wang, Wenda Zhang, Jingmin Zhang, Zhenfeng Duan, Youhong Hu, Yubing Zhou iD

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-18

DOI: 10.2147/dddt.s544583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Lin Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. Hauptthemen laut MEDLINE: Metformin, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Breast NeoplasmsPiperazinesProtein Kinase InhibitorsAntineoplastic AgentsHumansTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktAnimalsFemaleCell ProliferationPhosphatidylinositol 3-KinasesSignal TransductionMicePyridinesErb-b2 Receptor Tyrosine KinasesMice, NudeMice, Inbred BALB CDrug Screening Assays, AntitumorApoptosisDose-Response Relationship, DrugTumor Cells, CulturedMammary Neoplasms, ExperimentalCell Line, TumorStructure-Activity Relationship

Stichwörter der Autor:innen

CDK4/6 inhibitorHR+/HER2- breast cancerPI3K/AKT/mTOR pathwaymetforminpalbociclib

Substanzen

MetforminTOR Serine-Threonine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Proto-Oncogene Proteins c-aktMTOR protein, humanPiperazinesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsPyridines

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
  • Department of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
  • Department of Orthopedic Surgery, Sarcoma Biology Laboratory, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

ORCID-Profile: Yubing Zhou

Zitieren

APA

Zhu, L., Yang, J., Li, F., Wang, D., Zhang, W., Zhang, J., Duan, Z., Hu, Y., & Zhou, Y. (2026). Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway. Drug Design, Development and Therapy, Volume 20, 1-18. https://doi.org/10.2147/dddt.s544583

Vancouver

Zhu L, Yang J, Li F, Wang D, Zhang W, Zhang J, et al. Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway. Drug Design, Development and Therapy. 2026;Volume 20:1-18. doi:10.2147/dddt.s544583

BibTeX
@article{Zhu2026,
  author = {Zhu, Lin and Yang, Jiawen and Li, Fengmei and Wang, Dandan and Zhang, Wenda and Zhang, Jingmin and Duan, Zhenfeng and Hu, Youhong and Zhou, Yubing},
  title = {Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--18},
  doi = {10.2147/dddt.s544583}
}
Kostenlos starten →